SEHK:1541Biotechs
ImmuneOnco Biopharmaceuticals (Shanghai) (SEHK:1541) Stock Rally Meets Shrinking Revenue
ImmuneOnco Biopharmaceuticals (Shanghai) has ridden a strong wave of optimism into this earnings season, with the stock up about 39% over the past three months and closing at HK$4.08 on 27 August. The market is clearly paying for the story, not the profits, as the company still reported a loss in H1 2026 with basic earnings per share of C¥0.38 and net income of C¥164.19 million in the red.
The key question for investors now is whether that premium P/S multiple of around 11.9x still feels...